TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03157583

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NGBUV000A, (Expected SPF 30)
Description: A total of 2.0 ± 0.05 mg/cm2 (milligram per centimeter square of test site area) NGBUV000A (test product 1) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 1 will be applied to the test plates.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NGBUV000B, (Expected SPF 30)
Description: A total of 2.0 ± 0.05 mg/cm2 NGBUV000B (test product 2) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 2 will be applied to the test plates.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NGBUV000C, (Expected SPF 30)
Description: A total of 2.0 ± 0.05 mg/cm2 NGBUV000C (test product 3) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 3 will be applied to the test plates.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NGBUV000D, (Expected SPF 30)
Description: A total of 2.0 ± 0.05 mg/cm2 NGBUV000D (test product 4) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 4 will be applied to the test plates.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P3 Standard, (Expected SPF 16)
Description: A total of 2.0 ± 0.05 mg/cm2 reference P3 standard will be spread at the topical test sites on the back of each participant.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen formulation S2
Description: A total of 1.3 mg/cm2 of sunscreen formulation S2 will be applied to the test plates.

Intervention type: OTHER
Group type: OTHER
Intervention: Glycerin
Description: A total of 1.3 mg/cm2 of glycerin will be applied to the test plates.
Study: NCT03891628

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Attachment and Biobehavioral Catch-up
Description: Intervention targets include enhancing nurturance and following the child's lead, as well as supporting use of kangaroo care, swaddling, and breastfeeding.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Modified Developmental Education for Families
Description: Intervention targets include supporting developmental monitoring and parental engagement in activities that promote cognitive and motor development.
Study: NCT03461406

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibrin Sealant Grifols
Description: The FE Grifols solution was applied topically via drip or spray application.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EVICEL
Description: The EVICEL solution was applied topically via drip or spray application.
Study: NCT02814123

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 24-hour inpatient intervention
Description: Subjects will be admitted at the research facility at 7:30. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. Each 24-hour intervention visit includes 3 standardized meals (8:00, 12:00, and 17:00), an evening snack (21:00) and an overnight stay. The glucose level as measured by the real time sensor will be entered manually into the computer every 10 minutes. The insulin and pramlintide pumps' infusion rates will then be changed manually based on the computer generated recommendation, while still maintaining the ratio. The computer generated recommendations are based on a predictive algorithm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 24-hour inpatient intervention
Description: Subjects will be admitted at the research facility at 7:30. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. Each 24-hour intervention visit includes 3 standardized meals (8:00, 12:00, and 17:00), an evening snack (21:00) and an overnight stay. The glucose level as measured by the real time sensor will be entered manually into the computer every 10 minutes. The insulin and pramlintide pumps' infusion rates will then be changed manually based on the computer generated recommendation, while still maintaining the ratio. The computer generated recommendations are based on a predictive algorithm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 24-hour inpatient intervention
Description: Subjects will be admitted at the research facility at 7:30. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. Each 24-hour intervention visit includes 3 standardized meals (8:00, 12:00, and 17:00), an evening snack (21:00) and an overnight stay. The glucose level as measured by the real time sensor will be entered manually into the computer every 10 minutes. The insulin and pramlintide pumps' infusion rates will then be changed manually based on the computer generated recommendation, while still maintaining the ratio. The computer generated recommendations are based on a predictive algorithm.
Study: NCT03189758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observational Control Diet
Description: Participants will follow their usual or normal diet for 30 days (days 1-30) while under study observation.
Study: NCT04679493

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo single
Description: The volunteers will receive a single dose of the ID (1 or 2 capsules once)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC7 200 mg multiple
Description: The volunteers will receive multiple doses of the ID during 14 days (2 capsules daily, 100 mg each)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo multiple
Description: The volunteers will receive multiple doses of the ID during 14 days (2 capsules daily)
Study: NCT01275729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: dose: 1 mg / kg (iv) if the patient is furosemide naive or 1.5 mg/kg (iv) if the patient is not furosemide naive
Study: NCT03189758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled Dietary Sodium Restriction
Description: Participants will be provided with all meals and snacks daily, for 30 days (days 31-60). These meals should meet KDQOI guidelines for energy and protein (30-35 kcal/kg \& 1.2 g/kg) as well as low phosphorus, potassium, and sodium. The meals are formulated to less than 600-800 mg sodium each (\<2,000g/day) and will be ordered and delivered through momsmeals.com
Study: NCT02499250

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remote ischemic conditioning (TDFT-12-A2)
Description: The subjects will receive twice daily of 4×5min/5min ischemic/reperfusion of both arms (remote ischemic conditioning) over 30 days using the TDFT-12-A2 device produced by Shenzhen TDF Tai Smart technology Co., Ltd.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal medical treatment
Description: The subjects will receive optimal medical treatment according up-to-date guidelines, including adequate antiplatelet therapy, statins, β-blocker and nitrates, plus angiotensin converting enzyme inhibitor(ACEI)/angiotensin receptor blocker(ARB),oral anticoagulants, if necessary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimal medical treatment
Description: The subjects will receive optimal medical treatment according up-to-date guidelines, including adequate antiplatelet therapy, statins, β-blocker and nitrates, plus angiotensin converting enzyme inhibitor(ACEI)/angiotensin receptor blocker(ARB),oral anticoagulants, if necessary.
Study: NCT04072211

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Engerix-B
Description: Hepatitis B vaccine administered through intramuscular injection at 0, 1, and 6 months
Study: NCT03844360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: bortezomib was administered follow the doctor's advice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: eltrombopag was administered follow the doctor's advice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: imatinib was administered follow the doctor's advice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: dasatinib was administered follow the doctor's advice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: pegaspargase was administered follow the doctor's advice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Infective Drugs
Description: anti-infective drugs was administered follow the doctor's advice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor
Description: pegaspargase was administered follow the doctor's advice.
Study: NCT04165512

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: bupivacaine and triamcinolone
Description: a mixture of 4 mL 0.5% bupivacaine (marcaine) and 1 mL 40 mg triamcinolone (kenacort-a)
Study: NCT01578889

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-MAG vaccine
Description: Participants assigned to receive the HIV-MAG vaccine will receive 3 mg of the vaccine with bupivacaine, alone or admixed with one of three doses of the IL-12 pDNA adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-MAG vaccine
Description: Participants assigned to receive the HIV-MAG vaccine will receive 3 mg of the vaccine with bupivacaine, alone or admixed with one of three doses of the IL-12 pDNA adjuvant.
Study: NCT00443794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POLYCAP
Description: Capsule for Oral Administration once daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiazide + Ramipril+Atenolol+Aspirin
Description: Capsule (Blinded) for oral administration once daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Capsule (Blinded) for oral administration once daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: capsule (Blinded) for oral administration once daily for 12 weeks
Study: NCT04152109

Intervention type: OTHER
Group type: OTHER
Intervention: Without laying on of hands subgroup
Description: The patients will remain in bed supine with blindfolds. A volunteer will move close to the patient with hands behind and mentally repeat the alphabet or count during 5 minutes, around 8 weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Laying on of hands without Spiritual connection
Description: Participants included in this subgroup will be exposed to the laying on of hands with healing intent by volunteers. The patients will be blindfold in the supine bed during 5 minutes, around 8 weeks.
Study: NCT00336713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saredutant (SR48968C)
Description: oral administration (capsules)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration (capsules)
Study: NCT01288794

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diuretics plus human albumin
Description: The patients will receive standard medical treatment plus albumin infusion at the dose of 40 g twice weekly for 2 weeks, and then 40 g weekly for the rest of the study (up to 24 months).

Intervention type: DRUG
Group type: OTHER
Intervention: Diuretics (standard medical treatment)
Description: The patients will receive standard medical treatment (diuretics)
Study: NCT02089529

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen/Ibumetin with no information, positive information and neutral information

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen/Ibumetin with no information, positive information and neutral information
Study: NCT01447810

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focused rigidity bi-valve long arm cast
Description: Two focused rigidity bi-valve long arm (upper arm to finger tips) casts will be fabricated for each participant on day one of the constraint-induced therapy (CIT) program. Focused rigidity casting materials are water proof and latex/fiberglass free. Focused rigidity casting does not require use of a cast saw for removal thus decreasing potential for anxiety during the casting process. Casts will be fabricated by therapist trained in the casting technique.
Study: NCT02637778

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cardioprotective diet
Description: The 'cardioprotective diet' is characterized by (i) adequate energy intake, (ii) intake of carbohydrates, protein, fat according to the guidelines of the German Society of Nutrition (DGE e. V.), (iii) desirable intake of saturated fatty acids (SFA, 7 En%), monounsaturated fatty acids (MUFA, \> 10 En%), polyunsaturated fatty acids (PUFA, approx. 10 En%) and in particular n-3 LC-PUFA, (iv) encouraged consumption of vegetables, fruits, cereals, (v) salt and sugar reduction, (vi) avoiding of highly processed, calorie-dense, nutrient-poor food as well as (vii) encouraged physical activity.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cardioprotective diet + 3 g EPA + DHA/d
Description: The 'cardioprotective diet' is characterized by (i) adequate energy intake, (ii) intake of carbohydrates, protein, fat according to the guidelines of the German Society of Nutrition (DGE e. V.), (iii) desirable intake of saturated fatty acids (SFA, 7 En%), monounsaturated fatty acids (MUFA, \> 10 En%), polyunsaturated fatty acids (PUFA, approx. 10 En%) and in particular n-3 LC-PUFA, (iv) encouraged consumption of vegetables, fruits, cereals, (v) salt and sugar reduction, (vi) avoiding of highly processed, calorie-dense, nutrient-poor food as well as (vii) encouraged physical activity.The participants will consume additional n-3 LC-PUFA (3 g EPA+DHA/d)
Study: NCT00035464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azimilide Dihydrochloride
Description: 125 mg azimilide tablets, twice a day for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablets, twice a day for 6 months
Study: NCT02794662

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oxygen Environment
Description: FiO2 delivered by servo-controlled incubator

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Cannula Oxygen
Description: FiO2 delivered by nasal cannula
Study: NCT02089529

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen/Ibumetin with no information, positive information and neutral information

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with no information, positive information and neutral information

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with no information, positive information and neutral information
Study: NCT04152109

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laying on of hands by Spiritual Passe
Description: The participants will be subjected application of the laying on of hands by the volunteer who will give the Spiritist passe. Patients remain in the supine bed blindfolded for 5 minutes, around 8 weeks.
Study: NCT03860181

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcuticular Sutures - Surgeon 1
Description: This intervention closes incisions after shoulder arthroplasty using subcuticular sutures with Dermabond.The deep layer closure will require interrupted sutures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Metal Staples - Surgeon 2
Description: This intervention closes incisions after shoulder arthroplasty with metal staples. The deep layer closure will require interrupted sutures,

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRINEO - Surgeon 1
Description: The closure system uses the Dermabond PRINEO (which is similar to clear tape stuck over the wound) placed over running sutures for both the deep and subcuticular layer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRINEO - Surgeon 2
Description: The closure system uses the Dermabond PRINEO (which is similar to clear tape stuck over the wound) placed over running sutures for both the deep and subcuticular layer.
Study: NCT01931189

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NI-071
Description: 100mg/vial

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: 100mg/vial
Study: NCT00072215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine
Description: given IV
Study: NCT02561273

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous stem cell transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo peripheral blood stem cell transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT04864184

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normal physiologic rate breathing
Description: 2-minute breathing exercises will be completed every 15 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Slow breathing
Description: 2-minute breathing exercises will be completed every 15 minutes.
Study: NCT00779961

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Palatoplasty
Description: Routine palatoplasty will be performed under the supervision of one of five surgeons within the Division of Plastic Surgery at Sick Kids

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Palatoplasty
Description: Palatoplasty will be performed under the supervision of one of five surgeons within the Division of Plastic Surgery at Sick Kids
Study: NCT03323606

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gambling Internet Intervention
Description: The gambling Internet intervention consists of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gambling Internet Intervention
Description: The gambling Internet intervention consists of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Check Your Drinking
Description: A brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
Study: NCT04246814

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LG1
Description: Application of LASER AsGa 904nm 10 J/cm².

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LG2
Description: Application of LASER AsGa 904nm 8 J/cm².

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LG3
Description: Application of LASER AsGa 904nm 4 J/cm².

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CC
Description: Application of placebo LASER.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Dressing
Description: Application of Helianthus annuus oil dressing.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dressing
Description: Application of Helianthus annuus oil dressing.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dressing
Description: Application of Helianthus annuus oil dressing.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dressing
Description: Application of Helianthus annuus oil dressing.
Study: NCT01109771

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: permanent mesh fixation
Description: Permanent mesh fixation will be used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: permanent mesh fixation
Description: Permanent mesh fixation will be used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: absorbable mesh fixation
Description: Absorbable mesh fixation will be used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: absorbable mesh fixation
Description: Absorbable mesh fixation will be used.
Study: NCT02845076

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protocol for weaning of noninvasive ventilation
Description: 3 protocols for weaning of noninvasive ventilation will be compared

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protocol for weaning of noninvasive ventilation
Description: 3 protocols for weaning of noninvasive ventilation will be compared

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protocol for weaning of noninvasive ventilation
Description: 3 protocols for weaning of noninvasive ventilation will be compared